Insights and Limitations in Evaluating Testosterone Recovery With LHRH Antagonists and Agonists
The Prostate · 2026-07 · 86 (10) · 1176-1177
DOI: 10.1002/pros.24904 ↗At a glance
Leserbrief in The Prostate, published online on 2026-05-03. Written by Satı Coşkun Yazgan and 2 co-authors. Institution: Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey. Major MEDLINE topics: Testosterone, Prostatic Neoplasms, Gonadotropin-Releasing Hormone. 3 references. Funded by: The authors received no specific funding for this work..
Abstract (original language)
The article by Pae et al., titled “LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy,” provides valuable insights into the differential effects of LHRH antagonists and agonists on testosterone recovery in prostate cancer patients undergoing androgen deprivation therapy. While the study highlights the statistically significant accelerated recovery of testosterone with LHRH antagonists, several limitations warrant further discussion. Notably, the study does not adequately address the variability in the duration and formulations of LHRH agents (e.g., 1‐month, 3‐month, and 6‐month formulations), which may influence recovery times. Existing evidence suggests that long‐acting formulations are associated with prolonged recovery, raising questions about whether the observed differences are due to pharmacological properties or formulation duration. The clinical relevance of faster testosterone recovery remains uncertain, as the study does not evaluate its impact on patient‐reported outcomes such as quality of life, sexual function, or metabolic health. Future research should focus on stratifying analyses by formulation type and duration and assessing the clinical implications of testosterone recovery on patient‐centered outcomes to enhance the applicability of these findings to clinical practice.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
ORCID profiles: Yüksel Ürün
Funding
- The authors received no specific funding for this work.
Cite
APA
Yazgan, S. C., Yekedüz, E., & Ürün, Y. (2026). Insights and Limitations in Evaluating Testosterone Recovery With LHRH Antagonists and Agonists. The Prostate, 86(10), 1176-1177. https://doi.org/10.1002/pros.24904
Vancouver
Yazgan SC, Yekedüz E, Ürün Y. Insights and Limitations in Evaluating Testosterone Recovery With LHRH Antagonists and Agonists. The Prostate. 2026;86(10):1176-1177. doi:10.1002/pros.24904
BibTeX
@article{Yazgan2026,
author = {Yazgan, Satı Coşkun and Yekedüz, Emre and Ürün, Yüksel},
title = {Insights and Limitations in Evaluating Testosterone Recovery With LHRH Antagonists and Agonists},
journal = {The Prostate},
year = {2026},
volume = {86},
number = {10},
pages = {1176--1177},
doi = {10.1002/pros.24904}
}
EUVIMED